| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$884 |
Presentation to Investors
|
30 Jan 2025 8:58AM |
$0.875 |
$0.775 |
fallen by
11.43%
|
|
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$304 |
New Assays Confirm High Grade Silver in Tolmer Gold System
|
30 Jan 2025 8:57AM |
$0.265 |
$1.275 |
risen by
381.13%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade silver confirmed in the Tolmer gold system.
- Silver grades reached up to 312 g/t and gold grades up to 83.6 g/t.
- Strong association between gold and silver in quartz sulphide veining.
- New multi-element assays indicate broad zones of anomalous lead and copper.
- Follow-up drilling campaign of 1,500 to 2,000 meters has commenced.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Gold Limited (AGD) ORDINARY FULLY PAID |
Materials |
$99 |
Austral Gold Files Q4 2024 Quarterly Activity Report
|
30 Jan 2025 8:57AM |
$0.045 |
$0.160 |
risen by
255.56%
|
|
AGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Q4 2024 production increased to 3,669 GEOs.
- C1 costs decreased by 12.6% to US$1,877/oz.
- AISC decreased by 14.6% to US$2,064/oz.
- YTD 2024 production totalled 15,573 GEOs.
- Company forecasts 2025 production of 18,000-20,000 GEOs.
- Completed strategic initiative to replace equipment for higher availability.
- Executed Toll Processing Agreement for Casposo plant operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,518 |
Full Year 2024 Earnings Release Date
|
30 Jan 2025 8:57AM |
$4.850 |
$5.570 |
risen by
14.85%
|
|
| Australian Strategic Materials Limited (ASM) ORDINARY FULLY PAID |
Materials |
$185 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:56AM |
$0.475 |
$0.690 |
risen by
45.26%
|
|
ASM - Price-sensitive ASX Announcement
Full Release
Key Points
- Progressed the Dubbo Project Rare Earth Options Assessment to identify lower capital and shorter implementation pathways.
- Received initial instalment of A$5M grant from the Federal Government’s International Partnerships in Critical Minerals program.
- Delivered NdPr metal and NdFeB alloy to rare earth permanent magnet producers.
- Maintained strong cash flow discipline with a closing cash position of A$32.6M.
- Explored funding opportunities in Australia, Korea, the US, and Europe.
- Engaged with potential investors and government agencies across multiple jurisdictions.
- Continued development of heavy rare earth metallisation capability at the Korean Metals Plant.
- Completed a drilling campaign at Caspin's Mount Squires rare earth project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ausquest Limited (AQD) ORDINARY FULLY PAID |
Materials |
$80 |
Quarterly Activities and Cashflow Report
|
30 Jan 2025 8:56AM |
$0.041 |
$0.050 |
risen by
21.95%
|
|
AQD - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant porphyry copper-gold discovery at Cangallo Copper Project in Peru.
- Multiple wide intercepts of copper and gold mineralization confirmed in drilling.
- Raised ~$2.4 million through Non-Renounceable Rights Offer and Shortfall Placement.
- Quarter-end cash position of ~$2.1 million.
- Additional funds expected from South32 under Strategic Alliance Agreement in Q1 CY2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Buxton Resources Limited (BUX) ORDINARY FULLY PAID |
Materials |
$12 |
Quarterly Activities Report & Appendix 5B
|
30 Jan 2025 8:56AM |
$0.040 |
$0.034 |
fallen by
15%
|
|
BUX - Price-sensitive ASX Announcement
Full Release
Key Points
- Buxton reported high-grade assays from Graphite Bull Project, including 124m at 16.6% TGC.
- Ongoing qualification testwork by BTR on Graphite Bull ore.
- Cash balance at the end of the quarter was approximately AUD $1.1 million.
- Focus on exploration opportunities in both Australia and the USA.
- Joint venture developments including the Copper Wolf Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alternative Investment Trust (AIQ) ORDINARY UNITS FULLY PAID |
Financials |
$79 |
Update - Notification of buy-back - AIQ
|
30 Jan 2025 8:55AM |
$1.470 |
$1.478 |
risen by
0.51%
|
|
| Wellnex Life Limited (WNX) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Investor Presentation
|
30 Jan 2025 8:55AM |
$0.615 |
$0.092 |
fallen by
85.04%
|
|
| Locality Planning Energy Holdings Limited (LPE) ORDINARY FULLY PAID |
Utilities |
$20 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:55AM |
$0.145 |
$0.110 |
fallen by
24.14%
|
|
LPE - Price-sensitive ASX Announcement
Full Release
Key Points
- LPE is cashflow positive for the half year ending 31 December 2024
- LPE reduced its borrowings from $3.3m to $2.2m by repaying $1.1m to Roadnight Capital
- LPE chosen to provide energy solutions to Queensland’s largest social and affordable housing development in Cairns
- The Board reaffirms guidance for Financial Year 2025 to be a Net Profit of $3m to $3.5m
- LPE will manage the supply of electricity for the next 10 years for the Cairns project
- LPE's strategy includes improving customer satisfaction and retention, acquiring new sites, and increasing margins
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Triangle Energy (Global) Limited (TEG) ORDINARY FULLY PAID |
Energy |
$6 |
Quarterly Activities and Cashflow Report
|
30 Jan 2025 8:54AM |
$0.005 |
$0.003 |
fallen by
50%
|
|
TEG - Price-sensitive ASX Announcement
Full Release
Key Points
- Triangle holds a 78.75% interest in the Cliff Head Oil Field.
- The company is preparing to drill the Becos-1 exploration well in EP 437.
- Expected spud date for Becos-1 is late Q1 2025.
- Triangle has a 50% interest in several exploration permits in the UK.
- The company ended the quarter with $10.89 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Delta Lithium Limited (DLI) ORDINARY FULLY PAID |
Materials |
$161 |
Quarterly Activities Report and Appendix 5B
|
30 Jan 2025 8:53AM |
$0.170 |
$0.225 |
risen by
32.35%
|
|
DLI - Price-sensitive ASX Announcement
Full Release
Key Points
- Four-stage gold exploration program at Mt Ida targeting over 1 million ounces.
- Impressive drilling results from Mt Ida, including 2m at 9.8g/t Au.
- Continued studies for a Mt Ida gold standalone processing plant.
- Yinnetharra drill program completed with focus on resource mapping.
- Eureka Project sold for $1.5M cash and scrip.
- Nader El Sayed appointed as new chairman.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$87 |
Quarterly Activity Report & Appendix 4C
|
30 Jan 2025 8:52AM |
$0.215 |
$0.365 |
risen by
69.77%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 1 clinical trial in diabetic foot ulcer completed with positive efficacy data.
- Phase 2 trial in acute graft-versus-host disease recruitment over 40% complete.
- First patient treated in Phase 1 kidney transplantation trial.
- Phase 3 osteoarthritis trial completed patient treatment, results expected in 1H 2026.
- Company strengthened balance sheet with R&D Tax Incentive rebate and institutional placement.
- Strong cash balance of $10.51 million, forecast cash runway into mid 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Uvre Limited (UVA) ORDINARY FULLY PAID |
Materials |
$34 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:51AM |
$0.081 |
$0.180 |
risen by
122.22%
|
|
UVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong progress made on exploration program at Frome Downs Uranium Project.
- Phase 2 geophysical program completed with results pending.
- Targets identified are considered highly prospective for sediment-hosted uranium.
- New target area identified over strong structural complexity within basement rocks.
- Heritage Survey Agreement signed with Adnyamathanha Traditional Lands Association.
- Net cash balance approximately $2.7 million at end of quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,180 |
Second Quarter FY25 Business Update
|
30 Jan 2025 8:50AM |
$21.800 |
$18.870 |
fallen by
13.44%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- AUM increased to A$230.2 billion, up 3.6%
- Net outflows of A$3.8 billion affected AUM growth
- Corporate Trust's FUA grew by 2.5%
- Wealth Management's FUA increased by 1%
- Performance fees estimated to be A$15.9 million for 1H25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Asset Vision Co Limited (ASV) ORDINARY FULLY PAID |
Information Technology |
$34 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:50AM |
$0.025 |
$0.045 |
risen by
80%
|
|
ASV - Price-sensitive ASX Announcement
Full Release
Key Points
- 39% increase in total revenue to $1,235k for Q2 FY25
- 29% increase in licensing revenue to $943k
- ARR grew to $3.9m, a 15% increase for FY25
- Operating expenses reduced by 5% to $1,093k
- Positive operating cash flows of $625k
- Closing cash balance of $974k
- Deferred consideration for EagleSoft acquisition fully settled
- New customer proposals forecasted to drive further ARR growth
- Strategic partnerships enhance market offering
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$12 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:49AM |
$0.002 |
$0.060 |
risen by
2,900%
|
|
GMN - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade REE mineralisation found at Down Under Project.
- Assays pending for 98 further drill holes.
- Drill program designed for high-priority lithium targets.
- Significant copper anomalies identified at Jucas and Sao Juliao projects.
- Ongoing exploration aims to define additional drill targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hawk Resources Limited (HWK) ORDINARY FULLY PAID |
Materials |
$17 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:49AM |
$0.021 |
$0.032 |
risen by
52.38%
|
|
HWK - Price-sensitive ASX Announcement
Full Release
Key Points
- Lab assays confirm shallow high grade copper oxide mineralisation in Hawk drill holes into New Years prospect.
- Hole NY2024-DDH3 intersected 26m @ 1.3% copper from surface.
- Twelve new targets have been highlighted following modelling of magnetic and induced polarisation geophysical data.
- Cactus next steps include extending soil sampling and conducting an electromagnetic geophysical survey.
- Hawk's exploration has successfully characterised the mineralisation in the historical Cactus deposit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$9 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:49AM |
$0.180 |
$0.068 |
fallen by
62.22%
|
|
KNI - Price-sensitive ASX Announcement
Full Release
Key Points
- Updated Mineral Resource Estimate for Ertelien project stands at 40Mt @ 0.25% Nickel Equivalent.
- Significant focus on sustainable and ethical sourcing of battery metals.
- High-grade copper and zinc targets identified in Trøndelag district.
- Commitment to net zero carbon footprint in operations.
- Continued investments in exploration activities across multiple projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$28 |
Magmatic Exploration Activity Update
|
30 Jan 2025 8:48AM |
$0.051 |
$0.055 |
risen by
7.84%
|
|
MAG - Price-sensitive ASX Announcement
Full Release
Key Points
- Diamond drilling program commenced at Myall with 13 holes for 3,000m targeting high priority areas.
- Soil sampling at Boda Southwest completed with a significant gold anomaly west of Boda 4 Prospect.
- Best gold results from soil sampling at Boda Southwest were 0.24g/t Au and 0.11g/t Au.
- The Parkes Project has shown promising copper-gold anomalies with best results of 0.35ppm Au.
- A new exploration license, Glenbrook EL9731, has been granted covering 101.4 sqkm in the Parkes fault zone.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$19 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:48AM |
$0.006 |
$0.980 |
risen by
16,233.33%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical received $1.05 million R&D tax incentive.
- Ms. Lel Smits appointed as Non-Executive Director.
- MDR approval received for OncoSil device.
- G-BA approved a clinical trial for OncoSil device.
- First OncoSil treatment performed in Italy.
- First patient enrolled in Australia for TRIPP-FFX trial.
- Raised $8 million through equity placements.
- Cash balance stood at $8.463 million as of December 31, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ANZ Group Holdings Limited (ANZ) ORDINARY FULLY PAID |
Financials |
$109,807 |
Update - Notification of buy-back - ANZ
|
30 Jan 2025 8:47AM |
$30.620 |
$36.430 |
risen by
18.97%
|
|
| Purifloh Limited (PO3) ORDINARY FULLY PAID |
Utilities |
$7 |
Proposed issue of securities - PO3
|
30 Jan 2025 8:45AM |
$0.220 |
$0.220 |
fallen by
0%
|
|
| Mad Paws Holdings Limited (MPA) ORDINARY FULLY PAID |
Consumer Discretionary |
$61 |
Q2 FY25 Update
|
30 Jan 2025 8:45AM |
$0.080 |
$0.140 |
risen by
75%
|
|
MPA - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Operating Revenue of $7.7 million, up 2% on pcp.
- Group Cash EBITDA of $0.3 million, up 328% on pcp.
- Launch of the 'Press Paws' brand campaign to enhance visibility.
- Investment of $5.25 million by Seven West Media to support marketing efforts.
- Operational improvements leading to positive cash flow.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4C - Quarterly - 31 December 2024
|
30 Jan 2025 8:45AM |
$0.003 |
$0.028 |
risen by
833.33%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Results from specification testing of drug product announced following completion of GMP production run of PAT-DX1
- Internal development focus on PAT-DX3 and actively seeking partnering or licensing opportunities for PAT-DX1
- Implemented cost reduction initiatives while plans for a future R&D program and associated funding is finalized
- Received $1.3 million for the 2023/24 financial year under the Federal Government’s R&D Tax Incentive Scheme
- Cash and short-term investment balance of $2.2 million on 31 December 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
